| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Chardan Capital analyst Daniil Gataulin maintains Kodiak Sciences (NASDAQ:KOD) with a Neutral and maintains $14 price target.
HC Wainwright & Co. analyst Matthew Caufield maintains Kodiak Sciences (NASDAQ:KOD) with a Buy and raises the price targ...
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(1....
HC Wainwright & Co. analyst Matthew Caufield upgrades Kodiak Sciences (NASDAQ:KOD) from Neutral to Buy and raises the pr...
Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing a...
JP Morgan analyst Anupam Rama upgrades Kodiak Sciences (NASDAQ:KOD) from Neutral to Overweight and raises the price target f...